We are live on ! Find out more
SAGE

Sage Therapeutics
SAGE

Delisted

SAGE was delisted on the 30th of July, 2025.

Back to rankings

200 hedge funds and large institutions have $2.04B invested in Sage Therapeutics in 2022 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 68 increasing their positions, 60 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

259% more call options, than puts

Call options by funds: $23.4M | Put options by funds: $6.52M

24% more capital invested

Capital invested by funds: $1.65B → $2.04B (+$396M)

13% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 60

1.55% more ownership

Funds ownership: 86.31% → 87.86% (+1.5%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

4% less funds holding

Funds holding: 209 → 200 (-9)

23% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 30

Holders
200
Holders Change
-9
Holders Change %
-4.31%
% of All Funds
3.45%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
23
Increased
68
Reduced
60
Closed
30
Calls
$23.4M
Puts
$6.52M
Net Calls
+$16.9M
Net Calls Change
+$10.2M

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$26.9M
2
BlackRock
BlackRock
New York
+$22.4M
3
Fisher Asset Management
Fisher Asset Management
Washington
+$17.2M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$16.3M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$13.2M

Top Sellers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
-$23.7M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$17.7M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$11.7M
4
Morgan Stanley
Morgan Stanley
New York
-$8.99M
5
DTC
Deep Track Capital
Connecticut
-$5.55M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$14.8M +$300K +7,765 +2%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$14.3M +$477K +12,345 +4%
IHAM
28
Integral Health Asset Management
New York
$14M -$2.14M -55,257 -13%
Morgan Stanley
29
Morgan Stanley
New York
$13.3M -$8.99M -232,585 -41%
Franklin Resources
30
Franklin Resources
California
$11.8M +$8.66K +224 +0.1%
Hudson Bay Capital Management
31
Hudson Bay Capital Management
Connecticut
$11.6M – – –
American Century Companies
32
American Century Companies
Missouri
$8M +$842K +21,772 +12%
Bank of America
33
Bank of America
North Carolina
$7.64M +$1.52M +39,295 +25%
N
34
Nuveen
North Carolina
$7.17M -$149K -3,849 -2%
DCM
35
DAFNA Capital Management
California
$7.06M – – –
PA
36
Pinnacle Associates
New York
$6.61M -$218K -5,632 -3%
Rafferty Asset Management
37
Rafferty Asset Management
New York
$6.46M +$2.61M +67,491 +69%
Citadel Advisors
38
Citadel Advisors
Florida
$6.39M +$4.5M +116,406 +249%
IC
39
Ikarian Capital
Texas
$6.18M +$6.1M +157,805 New
AAP
40
Aristotle Atlantic Partners
Florida
$6.13M +$52.6K +1,360 +0.9%
Citigroup
41
Citigroup
New York
$5.96M +$1.97M +50,926 +50%
Two Sigma Investments
42
Two Sigma Investments
New York
$5.36M -$1.51M -39,172 -22%
Verition Fund Management
43
Verition Fund Management
Connecticut
$5.36M -$129K -3,345 -2%
Two Sigma Advisers
44
Two Sigma Advisers
New York
$5.3M +$2.62M +67,700 +100%
Squarepoint
45
Squarepoint
New York
$5.25M +$1.08M +27,858 +26%
Swiss National Bank
46
Swiss National Bank
Switzerland
$4.94M +$30.9K +800 +0.6%
BNP Paribas Financial Markets
47
BNP Paribas Financial Markets
France
$4.73M +$727K +18,804 +18%
SGA
48
Sector Gamma AS
Norway
$4.53M -$107K -2,780 -2%
ABG
49
Ally Bridge Group
New York
$4.32M +$4.26M +110,222 New
Barclays
50
Barclays
United Kingdom
$4.13M +$3.83M +99,159 +1,548%
1
2
3 4 5

SAGE Hedge Fund Activity: Q3 2022 in Review

200 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q3 2022, worth a combined $2.04B — up 24% from $1.65B a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of SAGE and 23 opened new positions — a net loss of 7 holders — while 60 trimmed existing stakes and 68 added.

The largest buyer was Janus Henderson Group, adding an estimated $26.9M. The largest seller was Marshall Wace, cutting an estimated $23.7M.

  • 200 institutional investors held Sage Therapeutics (SAGE) as of Q3 2022, down from 209 in Q2 2022.
  • Funds reported $2.04B of Sage Therapeutics stock for Q3 2022, up 24% quarter-over-quarter.
  • 23 funds opened new Sage Therapeutics positions in Q3 2022 and 30 closed out, a net change of -7 holders.
  • The largest Sage Therapeutics buyer in Q3 2022 was Janus Henderson Group, an estimated $26.9M added.
  • The largest Sage Therapeutics seller in Q3 2022 was Marshall Wace, an estimated $23.7M sold.

Based on aggregated 13F filings for Q3 2022.